View source for Chemistry:Ribonucleotide reductase inhibitor

'''Ribonucleotide reductase inhibitors''' are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides (building blocks of [[Biology:DNA|DNA]]).
Examples include:
* [[Chemistry:Motexafin gadolinium|motexafin gadolinium]].<ref name="pmid19121624">{{Cite journal|vauthors =Zahedi Avval F, Berndt C, Pramanik A, Holmgren A |title=Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd) |journal=Biochem. Biophys. Res. Commun. |volume= 379|issue= 3|pages= 775–9|date=January 2009 |pmid=19121624 |doi=10.1016/j.bbrc.2008.12.128 }}</ref>
* hydroxyurea<ref name="pmid12630679">{{Cite journal|vauthors =Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS |title=Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea |journal=Antivir. Chem. Chemother. |volume=13 |issue=5 |pages=305–14 |date=September 2002 |pmid=12630679 |doi= 10.1177/095632020201300506|doi-access=free }}</ref>
* [[Chemistry:Fludarabine|fludarabine]], [[Chemistry:Cladribine|cladribine]], [[Chemistry:Gemcitabine|gemcitabine]], [[Chemistry:Tezacitabine|tezacitabine]], and triapine<ref name="pmid12647987">{{Cite journal|vauthors =Tsimberidou AM, Alvarado Y, Giles FJ |title=Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies |journal=Expert Rev Anticancer Ther |volume=2 |issue=4 |pages=437–48 |date=August 2002 |pmid=12647987 |doi=10.1586/14737140.2.4.437 |s2cid=30047759 }}</ref>
* [[Chemistry:Gallium maltolate|gallium maltolate]], [[Chemistry:Gallium nitrate|gallium nitrate]]<ref
name="PharmRev">{{Cite journal| author=Bernstein LR | title = Mechanisms of therapeutic activity for gallium | journal = Pharmacol. Rev. | year = 1998 | volume = 50 | pages = 665–682 | url = http://pharmrev.aspetjournals.org/cgi/reprint/50/4/665.pdf | pmid=9860806 | issue=4}}</ref>
* [[Chemistry:Tezacitabine|Tezacitabine]], [[Chemistry:Tezacitabine|Tezacitabine]]<ref>{{cite journal | url=https://pubmed.ncbi.nlm.nih.gov/8137252/ | pmid=8137252 | title=Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase | journal=Cancer Research | date=15 March 1994 | volume=54 | issue=6 | pages=1485–1490 | last1=Bitonti | first1=A. J. | last2=Dumont | first2=J. A. | last3=Bush | first3=T. L. | last4=Cashman | first4=E. A. | last5=Cross-Doersen | first5=D. E. | last6=Wright | first6=P. S. | last7=Matthews | first7=D. P. | last8=McCarthy | first8=J. R. | last9=Kaplan | first9=D. A. }}</ref> A chemotherapy candidate nucleotide analogue that failed in clinical trials due to on-target toxicity ([[Medicine:Febrile neutropenia|febrile neutropenia]]).<ref>{{cite web | url=https://pubchem.ncbi.nlm.nih.gov/compound/9925544 | title=Tezacitabine monohydrate }}</ref>

==See also==
* [[Biology:Ribonucleotide reductase|Ribonucleotide reductase]]

==References==
{{Reflist}}

==External links==
* [http://www.cancer.gov/dictionary?CdrID=349442 Ribonucleotide reductase inhibitor] entry in the public domain NCI Dictionary of Cancer Terms

{{NCI-cancer-dict}}

{{Enzyme inhibition}}
{{Intracellular chemotherapeutic agents}}

[[Category:Oxidoreductase inhibitors]]


{{Sourceattribution|Ribonucleotide reductase inhibitor}}